GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
This is the first drug to receive a recommendation for this preventative indication in the European Union
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
The antibody was designed and developed at Abzena’s Cambridge, UK,
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
